** Cancer therapy maker Novocure's NVCR.O shares up 4.3% at $16.25
** NVCR says its cancer therapy, Optune Lua, to treat a type of lung cancer, has received a CE (Conformité Européenne) mark in Europe
** The CE marking certifies that a product has met EU health, safety, and environmental requirements
** CE mark approval is based on late-stage study results that showed the therapy, which uses electric fields to kill cancer cells while sparing most nearby healthy cells, also improved survival rates of patients over 8 years - NVCR
** CE mark comes after FDA's approval of Optune Lua in October 2024
** As of last close, NVCR had fallen 45.% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.